Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Un-(User Fee) Funded Priorities

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency tells stakeholders that five PDUFA proposals which were not included in the commitment letter will be funded with existing resources.

You may also be interested in...



FDA Ponders Trimming PDUFA Programs

Acting Commissioner Ostroff considers whether all aspects of the user fee program are delivering maximum added value.

FDA Ponders Trimming PDUFA Programs

Acting Commissioner Ostroff considers whether all aspects of the user fee program are delivering maximum added value.

Does PDUFA Need A Haircut? FDA Ponders Trimming Its Responsibilities

Acting Commissioner Ostroff wonders if all aspects of user fee program are delivering maximum added value.

Related Content

Topics

UsernamePublicRestriction

Register

PS072510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel